Salary rift emerges across pharma
There is a growing divide in Australian pharma between what companies want to pay and what workers are willing to accept with the fallout being felt across industry
There is a growing divide in Australian pharma between what companies want to pay and what workers are willing to accept with the fallout being felt across industry
A baby with a very rare disease has received treatment otherwise unavailable in Australia thanks to a new Innovative Therapies Pathway - and it only took six weeks
The company has put money down for a potential first-in-class rival in the lucrative obesity space for an asset that allows patients to shed kilos but preserves muscle
Dose-limiting toxicities has scuppered an otherwise promising cancer program, seeing a local company cut jobs and scope out possible ways to remain a going concern
Almost three-quarters of the new PBS listing submissions considered by PBAC in July won green light, however many highly anticipated drugs were delivered a blow
Results of a year-long study conducted in Australia and sponsored by Pfizer has been published in JAMA Pediatrics this month reinforcing the effectiveness of its maternal immunisation
Companies will be able to test messaging and materials in days, rather than months, with responses based on real clinician-patient conversations
A brutal downsizing is coming to pharma with a broad range of roles simply ceasing to exist. Australian experts have revealed the skills and capabilities needed to survive
The Golden Target Awards shortlist is out with a strong showing of pharma PR campaigns competing to take home a trophy across a number of categories
Aussie breakthrough could see a new gene therapy become the first targeted treatment for a range of inherited heart diseases promising sick kids a future without progressive heart failure
Last week the TGA approved a new antibiotic along with a new strength of a lung cancer drug plus generics, and OTCs
Company 'disappointed' after the PBAC knocked back a revised submission for the only TGA-approved biologic for uncontrolled severe atopic dermatitis in children under 12 over due to price
Researcher recognised for her work in determining why some people suffer life-threatening illnesses from respiratory viruses, potentially transforming care
The Head of the TGA has threatened continued "strong compliance and enforcement action" after the Regulator issued its second significant fine in just over a month
This drug is still months off being filed for approval but there's already a booming black market with the Big Pharma that developed it taking a tough legal stand
Job movements continue across industry and it's not always for somewhere new - with two industry executives returning to companies where they've worked before